

April 16, 2025

AmeriHealth Caritas Next Formulary GLP-1 Medications

AmeriHealth Caritas Next formulary GLP-1 medications (Mounjaro, Ozempic, Rybelsus, Trulicity) are updating from requiring a step therapy with Metformin to a prior authorization requiring the following:

Initial authorization:

- Diagnosis of Type 2 Diabetes Mellitus
- Requested dose is appropriate per labeling
- Age restriction is appropriate per package insert
- Documentation of laboratory results that meet one of the following values:
 - o A1C ≥ 6.5
 - o Fasting plasma glucose (FPG) ≥ 126 mg/dL
 - o 2-hour plasma glucose (PG) ≥ 200 mg/dL during OGTT (oral glucose tolerance test)
 - o Random Plasma Glucose ≥ 200 mg/dL

Reauthorization:

- Documentation of positive clinical response to therapy (e.g., A1C lab results)
- Requested dose is appropriate per labeling
- Age restriction is appropriate per package insert

The above prior auth criteria is effective 4/15/2025 for new starts and 7/1/2025 for our current members on a GLP-1 medication.

If you have any questions, please reach out to AmeriHealth Caritas Next Pharmacy Services at 1-833-733-7967.